近日,他克莫司滴眼液在电商平台大幅涨价冲上微博热搜,部分商家将其标价推高至3000余元。 《每日经济新闻》记者了解到,尽管他克莫司滴眼液的核心专利已于2023年到期,但目前仅有日本千寿制药一款产品获批上市。 一位从事眼科药物研究的行业人士表示,国内至今没有一款等效的工业化仿制药获批上市的根本原因,在于高端滴眼液领域存在着极高的药学与制剂工艺壁垒。“中国眼科制药产业长期以低端普药、抗生素/激素的...
Source Link近日,他克莫司滴眼液在电商平台大幅涨价冲上微博热搜,部分商家将其标价推高至3000余元。 《每日经济新闻》记者了解到,尽管他克莫司滴眼液的核心专利已于2023年到期,但目前仅有日本千寿制药一款产品获批上市。 一位从事眼科药物研究的行业人士表示,国内至今没有一款等效的工业化仿制药获批上市的根本原因,在于高端滴眼液领域存在着极高的药学与制剂工艺壁垒。“中国眼科制药产业长期以低端普药、抗生素/激素的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.